Show simple item record

dc.contributor.advisorRiederer, Kathleen
dc.contributor.authorChase, Patrick
dc.date.accessioned2008-03-06T18:56:07Z
dc.date.available2008-03-06T18:56:07Z
dc.date.copyright2007-04-27
dc.date.issued2007-04-27
dc.identifier.urihttp://hdl.handle.net/10920/4317
dc.description1 broadside : ill.
dc.description.abstractStaphylococcus aureus is an aerobic gram positive bacterium that can cause harmful skin infections and bacteremia. Some strains of S. aureus have become resistant to synthetic penicillin (Methicillin) and therefore need to be treated with Daptomycin, a novel lipopeptide antibiotic that was approved by the Food and Drug Administration (FDA) for treatment of gram positive skin infections in 2003. Two patients at St. John Hospital & Medical Center (Detroit, MI) were on prolonged treatment of Daptomycin for S. aureus bacteremia and blood cultures showed non-susceptibility to the drug. Both patients’ blood cultures were shown to develop non-susceptibility to Daptomycin after 5 and 7 days of treatment.
dc.description.sponsorshipSt. John Hospital and Medical Center (Detroit, Mich.)
dc.description.sponsorshipKalamazoo College. Department of Biology. Diebold Symposium, 2007
dc.description.tableofcontentsAbstract -- Introduction -- Materials and methods -- Results -- Conclusions -- Acknowledgments
dc.language.isoen_USen
dc.publisherKalamazoo College
dc.subject.lcshStaphylococcal disease
dc.titleResistance to Daptomycin in the Treatment of Methicillin Resistant Staphylococcus aureus Bacteremiaen


Files in this item

Thumbnail

This item appears in the following Collection(s)

  • Diebold Symposium Posters and Schedules [320]
    Poster and oral presentations by senior biology majors that include the results of their Senior Individualized Projects (SIPs) at the Diebold Symposium. Abstracts are generally available to the public, but PDF files are available only to current Kalamazoo College students, faculty, and staff.

Show simple item record